Generic dossier
Tafluprost (preservative-free)
0.0015% · Ophthalmic solution · Ophthalmic
Product data
- Strength
- 0.0015%
- Dosage form
- Ophthalmic solution
- Dosage-form group
- Ophthalmic
- Therapeutic area
- Ophthalmic
- Market
- EU/US
- Status
- Dossier target · Jun 2027
- Development status
- 1-year lab-scale stability completed
- Portfolio
- Generic dossier
Start a conversation
Where does your programme stand?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.
Business enquiries: vasanthi@kmshc.com · +91 97898 75194V-23